# ZEISS Ventures

> ZEISS Ventures is a VC fund in Oberkochen backing Health Care and Semiconductor. See 10 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Oberkochen, Germany
- Total investments: 10
- Last investment: Aug 2026
- Lead investor: 80%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/showcase/zeiss-ventures/
- Website: https://www.zeiss.com/corporate/en

ZEISS Ventures is a cooperate venture arm of the ZEISS Group.

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $5.2M–$23M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 1 | 10% |
| Semiconductor | 1 | 10% |
| Medical Device | 1 | 10% |
| Machine Learning | 1 | 10% |
| Artificial Intelligence | 1 | 10% |

6 industries tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Germany | 1 | 10% |
| United Kingdom | 1 | 10% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SeeTrue Technologies | SeeTrue Technologies creates world’s most-advanced customizable and robust eye-tracking solutions | $2.5M | Seed | Aug 05, 2026 |  |
| Hypervision Surgical | Making surgeries more precise, safer and faster. Guiding the future of surgery using AI-powered hyperspectral imaging. | $23M | Series A | Apr 29, 2026 |  |
| Custom Surgical | Custom Surgical is a pioneering medical technology company specializing in eyecare, recognized for its innovative product, MicroREC Connect, an AI-powered PACS platform. This groundbreaking platform, in conjunction with the company's digitalization tools, streamlines data management in eyecare, seamlessly integrating data from various devices,fostering improved patient diagnosis, and enhancing workflow efficiency. Moreover, Custom Surgical's transparent and affordable pricing models enable a frictionless entry point to the platform. With over 1600 MicroREC systems distributed the world, the company is making a significant global impact to democratize the access to eyecare diagnostics | $4.1M | Seed | Feb 19, 2026 |  |
| arcoris bio | arcoris bio provides spatial multiomics solutions focused on transforming biomedical research and diagnostics through innovative and accessible technologies. | $7.8M | Seed | Nov 06, 2025 |  |
| Lidrotec | Lidrotec aim to expand the application potential of processing with ultra-short pulse lasers. | $13.5M | Series A | Jun 25, 2025 |  |
| Odne | Lumendo is a medtech startup that develops light-active medical fillers for elegant and time saving surgeries. The fillers allow time-saving surgery for the best patient outcome. These can be used to form implants in any cavity inside the body. Lumendo was founded on 2018 and is headquartered in Renens, Switzerland. | $5.2M | Series A | Jun 12, 2025 |  |
| Surgify | Surgify are currently preparing the commercialization of a novel technology for bone surgery at Aalto University with financial support from Tekes (Finnish Funding Agency for Innovation). To enable continuous communication with clinicians, they have been working in close cooperation with Neurosurgical Department of Helsinki University CentralHospital, part of HUS (The Hospital District of Helsinki and Uusimaa). | $7.9M | Series A | May 27, 2025 |  |
| Mindpeak | Mindpeak provides artificial intelligence solutions that automate tissue diagnostics for cancer treatment. The company focuses on enhancing the efficiency of cancer experts by streamlining tasks such as cell and biomarker quantification. These tools integrate seamlessly into existing workflows, allowing specialists to concentrate on criticaldecision-making processes. | $15.3M | Series A | Sep 30, 2024 |  |
| Hypervision Surgical | Making surgeries more precise, safer and faster. Guiding the future of surgery using AI-powered hyperspectral imaging. | $8.1M | Seed | Jun 01, 2023 |  |
| InSphero | InSphero AG develops organotypic biological 3D microtissues and microtissue-based assays for biochemical compounds screening and predictive drug testing applications. It offers human prostate and mammary carcinoma, and rat liver microtissues. The company also provides compound toxicity testing, cell-invasion assays, stem-cell research, cell-to-cellinteraction, regenerative medicine, tissue engineering, and cell-to-extracellular matrix interaction services. In addition, it involves in study of transcriptomics, proteomics, and metabolomics. Further, the company provides custom development services, which include microtissue development, H and E stained paraffin sections, growth characteristics data, and morphometric data. Its microtissue system enables the generation of various model systems using either tumor-derived cells to reconstitute primary tumors or primary cells to mimic structure and function of diverse organ tissues. InSphero AG was founded in 2009 and is based in Zurich, Switzerland. |  | Venture - Series Unknown | Mar 31, 2023 |  |

10 of 10 investments shown.

## Co-investors
- [GOOSE Capital](https://shizune.co/investors/profile/goose-society-of-texas) — VC Fund, 2 deals together
- [HERAN Partners](https://shizune.co/investors/profile/heran-partners) — VC Fund, 2 deals together
- [Lam Capital](https://shizune.co/investors/profile/lam-capital) — VC Fund, 2 deals together
- [Life Extension Ventures](https://shizune.co/investors/profile/life-extension-ventures) — VC Fund, 2 deals together
- [redalpine](https://shizune.co/investors/profile/redalpine-venture-partners) — VC Fund, 2 deals together
- [AI.FUND](https://shizune.co/investors/profile/ai-fund) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Business Finland](https://shizune.co/investors/profile/tekes) — VC Fund
- [Lifeline Ventures](https://shizune.co/investors/profile/lifeline-ventures) — VC Fund
- [Tesi](https://shizune.co/investors/profile/tesi) — VC Fund

## Featured in investor lists
- [Medical VC Funds in Finland](https://shizune.co/investors/medical-vc-funds-finland)
- [Wellness VC Funds in Switzerland](https://shizune.co/investors/wellness-vc-funds-switzerland)

## FAQ

### What does ZEISS Ventures invest in?

ZEISS Ventures invests primarily in Health Care, Semiconductor and Medical Device startups, most often at Series A stage. Most of the 10 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is ZEISS Ventures's check size?

ZEISS Ventures typically joins rounds of $5.2M–$23M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds ZEISS Ventures participates in.

### When did ZEISS Ventures last invest?

The most recent investment recorded for ZEISS Ventures closed in Aug 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co